Select vitamin brands aimed at eye and brain health had significant sales gains in 2016, according to Kline’s just-published Nonprescription Drugs USA 2016 study. Preservision adult multivitamins for eye health, which is marketed by Valeant Pharmaceuticals, experienced sales growth over 20.0% in 2016, driven by a switch from print to television media for the brand and claims that “only Preservision’s formula has been proven to reduce the risk of progression of moderate to advanced Age-related Macular Degeneration (AMD) in the National Eye Institute’s Age-related Eye Disease Study (AREDS).” Preservision contains high potency antioxidants and minerals, such as 1,000mg omega-3 fatty acids, lutein, and zeaxanthin, and claims to be “the only clinically proven formula.”Continue reading
Steady supply and distribution of brands that had previously been recalled continued to experience strong sales gains in 2016, according to Kline’s research for its annual Nonprescription Drugs USA study.
Johnson & Johnson’s Tylenol and Motrin brands, which had been off the market for several years, are making a substantial comeback supported by strong advertising and marketing. GlaxoSmithKline’s Excedrin brands was also temporarily off the market and enjoys steady gains in 2016 as it is in predictable supply with retailers again. All other major OTC pain reliever brands and store brands experience flat to declining sales in 2016 with the exception of Prestige Brands’ BC and Goody’s pain relief powders and Doan’s (Dr. Reddy’s Laboratories).Continue reading
One area that shows much higher rates of growth than monograph OTC digestive products are brands that offer claims of improving digestive health and immunity. Probiotics, prebiotics, and digestive enzymes all offer prevention of digestive ailments, including constipation, and improve regularity. Many brands in these market segments are able to achieve high double-digit gains as they are used on a daily basis, and consumers, therefore, make frequent repeat purchases. Kline’s upcoming Digestive Health, Immunity, and Probiotics: U.S. Market Analysis and Opportunities study will contain complete analyses of this market and sales, growth, and market shares of the leading brands and companies.Continue reading
The U.S. OTC market posted 2.2% growth overall from 2015 to 2016, according to Kline’s venerable Nonprescription Drugs USA annual market assessment study. However, topical analgesics, nasal allergy medications, herbal products, and contraceptive products posted much higher rates of dollar sales growth. The calendar year of 2016 was marked as being a weak cold and flu season, which put a damper on sales of many OTC upper respiratory brands and market segments. However, in contrast, nasal allergy sprays grew by double digits, driven by growth of newer Rx-to-OTC switch brands, Flonase Allergy Relief (GlaxoSmithKline), and the addition of Rhinocort Allergy Spray by Johnson & Johnson to the market. This rapid uptake of nasal allergy sprays resulted in a small decline in sales of oral allergy medications. Continue reading
Laura Mahecha, our healthcare industry manager, recently attended CHPA’s President’s Forum in Malvern, PA, to speak about the dynamic adjacent OTC categories that make a mark on traditional OTCs. One of these categories is natural OTCs, which refers to non-drug, non-monograph, plant- or supplement-based, or homeopathic products that often make claims of support, prevention, maintenance, and/or treatment of minor conditions or ailments. Such products are increasingly popular among consumers and have posted healthy growth recently.
In fact, sales of natural OTCs are up 11.4% compared with 4.2% growth for traditional OTCs over the same timeframe, according to the last published editions of Kline’s Nonprescription Drugs USA and Natural OTCs: Impact of Non-drug Products on the U.S. OTC Market. Natural products offering enhanced immunity for cough/cold and digestive immunity account for more than two-thirds of the natural OTC market, but products touting improved brain health/memory are growing at the fastest pace among natural OTC brands.Continue reading
Chronic pain continues to be an area consumers seek to treat with a variety of methods including prescription drugs, OTC medications, topical rubs, and pain management devices. The increasing U.S. aging population will continue to generate the demand for pain relief products. Seniors increasingly seek to mitigate pain associated with old age and sedentary lifestyles, thereby increasing sales. The baby boomer population is the most rapidly increasing age segment in the United States, with an estimated 23% of the population reaching 55 years of age in 2015. The physically active baby boomer generation is concerned about maintaining health and wellness, far more so than previous generations.Continue reading
Recent switches, the return of major brands that had been previously recalled, and branded innovations continue to drive the nonprescription drugs market in the United Sates. Above-average growth rates within some categories are propelled by newly switched brands being launched, which are bringing prescription users to the OTC market.
During this live webinar, Sai Swaroop, Kline’s Senior Consultant, will reveal some interesting key findings from our recently published Nonprescription Drugs USA report. The session will take place on Tuesday, July 12, 2016 at 11:00 AM EDT | 17:00 PM CET.Continue reading
Driven by the solid growth of most markets, sales of the U.S. OTC market increase by 3% in 2015. Particularly high gains are seen in the allergy and antacids markets, fueled by recent Rx-to-OTC switch brands, such as Flonase Allergy Relief by GlaxoSmithKline and Nexium 24HR by Pfizer. Recently released sales data from our annual Nonprescription Drugs USA market study pegs the upper respiratory market at more than 7% growth and digestive products at almost 5% from 2014 to 2015. These growth rates are well above the average growth for these markets, propelled by new switch brands being launched and bringing in previous users of these medications from the prescription market to the OTC market.Continue reading
The upper respiratory self care market is crowded with many brands, ingredients, claims, and offers. Walking down the cold and allergy aisles of retail stores can make consumers dizzy from the assortment and sheer number of products on shelves, each making similar but not exactly the same claims. This makes the cold and allergy aisle a complex section for consumers to navigate. Much of this complexity is rooted in the fact that colds, the flu, and allergies all affect the upper respiratory system—yet each condition has symptoms that set it apart, as well as symptoms that overlap with each other. Continue reading
Growth of the U.S. nonprescription market is primarily driven by Rx-to-OTC switches as they bring former prescription users to the OTC market. Due to an increasingly favorable regulatory environment, Kline forecasts robust Rx-to-OTC switch activity over the next five years with several all new OTC categories emerging along with many new brands entering the market into existing categories.
If all switches occur over the next five years (even those with low to moderate likelihood), the market is forecast to increase at a compound annual growth rate (CAGR) of 5% by 2019, according to the recently published report covering Rx-to-OTC Switch Pipelines in the United States. By contrast, if the only switches that come to market are those that are predicted to have moderate to high likelihood of approval and launch, the overall OTC market will expand by a CAGR of 3.6% over the next five years.Continue reading